Medulloblastoma is a fast-growing brain tumor that requires precise genetic classification for effective treatment.

Health · Published 3 October 2026 Swipe more like this →

In short: As the most common cancerous brain tumor in children, medulloblastoma originates in the cerebellum, the brain's center for balance and coordination. While once viewed as a single entity, modern medicine now identifies four distinct molecular subgroups, each with unique genetic signatures that dictate how the cancer behaves and responds to therapy.

Medulloblastoma is classified as a grade 4 tumor, meaning it is malignant and grows rapidly. It typically forms in the cerebellum, the lower back portion of the brain. Because of its location, the tumor often obstructs the flow of cerebrospinal fluid, leading to hydrocephalus—a dangerous buildup of pressure inside the skull. This pressure is responsible for many of the hallmark symptoms, including morning headaches, nausea, vomiting, and balance issues. Unlike many other brain tumors, medulloblastoma is known for its ability to spread through the cerebrospinal fluid to other parts of the central nervous system, including the spinal cord.

The landscape of diagnosis has shifted from simple microscopic appearance to molecular profiling. Researchers have identified four primary subgroups: WNT-activated, SHH-activated, Group 3, and Group 4. WNT-activated tumors are generally the least common but often carry the best prognosis, while Group 3 tumors, frequently seen in young children, tend to be more aggressive. SHH-activated tumors, named for the sonic hedgehog signaling pathway, can occur across all age groups. Understanding these molecular differences is critical because they guide risk stratification and treatment intensity, helping clinicians decide how much surgery, radiation, or chemotherapy is necessary.

Treatment typically begins with surgical resection to remove as much of the tumor as possible, followed by craniospinal radiation and chemotherapy. While the diagnosis is life-altering, the outlook has improved significantly; the relative five-year survival rate is now approximately 80.6 percent. However, outcomes remain highly variable, depending on the patient's age, the specific molecular subgroup, and the extent of the tumor's spread at the time of diagnosis. Ongoing research into targeted therapies and proton beam radiation aims to further improve survival while reducing the long-term cognitive and physical side effects of treatment.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• Metastases outnumber primary brain tumors four to one
• Gliomas arise from the brain's support cells, not the nerve cells themselves.
• Meningiomas are the most common primary brain tumor, yet often remain silent for years.
• Neurofibromatosis tumours grow from the nerves' support cells, not neurons
• Glioblastoma accounts for about half of malignant brain tumors
• Why the metals in your body are a double-edged sword for your health
• A broken jaw is more than just pain; it can threaten your ability to breathe.
• Why methamphetamine creates a perfect storm for rapid tooth decay
• Can we accurately predict which injured patients require specialized trauma center care?
• The genetic glitch that causes male infertility without changing outward appearance
• Why the world's leading cause of disability is often a mystery to medicine
• The versatile white blood cells that shape your immune landscape

More in Morbidity · More in Health · Latest · A–Z · All topics